Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML: Results from Matched Comparisons to Historical Controls

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-136957

Published: 2020

Journal Articles

Post Allograft Rituximab Responsive Cytopenia (RRC)

Samar Kulkarni, MD, John Murray, RGN, MSc, David Kaye, MSc, Michael Dennis, FRCPath, Anna Castleton, FRCPath, Mohd K Mamat, MRCP, James Cavet, Daniel Wiseman, FRCPath, Tim Somervaille, FRCPath, Sven Sommerfeld, MRCP, Richard Chasty, FRCPath, Adrian Bloor, FRCPath

Blood (2019) 134 (Supplement_1): 5645.

https://doi.org/10.1182/blood-2019-132214

Published: 2019

Journal Articles

Results of a Phase 2 Trial of the Monocyte-Targeted Histone Deacetylase Inhibitor Tefinostat (CHR-2845) in Chronic Myelomonocytic Leukemia (CMML) — the UK Monocle Study

Steven Knapper, DM, Michael Dennis, MD, MRCP, FRCPath, Mark W Drummond, PhDMD, Robert K. Hills, MA, DPhil, MSc, Richard James Dillon, MA, PhD MRCP, FRCPath, Christopher Pocock, MD PhD, Dominic J. Culligan, Paresh Vyas, Daniel Wiseman, MB, ChB, Joanna Zabkiewicz, PhD, Marie Hodges, PhD MSc, Catherine Cargo, MB, FRCPath, Jan Taylor, PhD MSc, BSc, Laura Upton, Melissa Wright, David Bowen, MD PhD

Blood (2018) 132 (Supplement 1): 1818.

https://doi.org/10.1182/blood-2018-99-110356

Published: 2018

Journal Articles

Children and Adults with Steroid-Refractory Acute Graft-Versus-Host Disease Respond to Treatment with the Mesenchymal Stroma Cell Preparation "MSC-FFM": Treatment Results for 92 Consecutive Patients

Blood (2018) 132 (Supplement 1): 603.

https://doi.org/10.1182/blood-2018-99-110599

Published: 2018

Journal Articles

The Achievement of Complete Remission Is Associated with Improved Quality of Life in Non-Intensively Treated Patients with Acute Myeloid Leukemia: Results of the UK NCRI LI-1 Tria

Robert K. Hills, MA,DPhil,MSc, Ian Thomas, Alan K. Burnett, MD, Claire Jane Hemmaway, MD, Helen Dignum, Nigel H. Russell, Michael Dennis, MDMRCP,FRCPath

Blood (2018) 132 (Supplement 1): 372.

https://doi.org/10.1182/blood-2018-99-116173

Published: 2018

Journal Articles

Therapy-Related Myeloid Neoplasms with Balanced Chromosome Rearrangements Frequently Arise from Pre-Existing Clonal Haematopoiesis

Richard Dillon, MA, PhD MRCP, FRCPath, Jelena Jovanovic, PhD, Nicola Potter, PhD, Nicola Foot, MSc, Matthew J Ahearne, MD MBBS, Sandrine Jayne, PhD, Michael Dennis, MD MRCP, FRCPath, Ann E. Hunter, MBBS, FRCP, FRCPath, Martin J.S. Dyer, Paresh Vyas, Lynn Quek, FRCPath, DPhil, MBBS, Nigel H. Russell, Robert K. Hills, MA, DPhil, MSc, Ellen Solomon, PhD, David Grimwade, PhD MRCP, MRCPath

Blood (2018) 132 (Supplement 1): 2570.

https://doi.org/10.1182/blood-2018-99-114233

Published: 2018

Journal Articles

Treatment Disparities in Minority Groups with Multiple Myeloma at a Large Safety-Net Hospital

Michael Dennis, MD, Diana Cirstea, MD, Asaf Maoz, MD, Adam Lerner, MD, Ami K. Patel, MD, Shayna Sarosiek, MD

Blood (2018) 132 (Supplement 1): 4864.

https://doi.org/10.1182/blood-2018-99-118472

Published: 2018

Journal Articles

An Evaluation of 17 Years of Low Dose Cytarabine As Therapy for AML Patients Not Fit for Intensive Treatment, Including Patients with Adverse Cytogenetics, Shows Improving Survival, Potential Underutilisation and Highlights the Need for New Therapy

Michael Dennis, MDMRCP,FRCPath, Robert K. Hills, DPhil, Nigel H. Russell, Mhairi Copland, PhD MBBChir, FRCP, FRCPath, Ian Thomas, Mary Frances Frances McMullin, MB,Bch BAO, MD FRCPath, Sahra Ali, Alan K. Burnett, MD

Blood (2017) 130 (Supplement 1): 3874.

https://doi.org/10.1182/blood.V130.Suppl_1.3874.3874

Published: 2017

Journal Articles

Combined Azacitidine and High Dose Lenalidomide Therapy Is Well Tolerated and Clinically Active in Patients Who Relapse after Allogeneic Stem Cell Transplantation for Actue Myeloid Leukemia: Results of the Uk Trials Acceleration Programme Viola Trial

Charles Craddock, Wendy Ingram, Daniel Slade, Andrea Hodgkinson, BSc(Hons),PhD, Francis J. Mussai, MA, MD DPhil, Carmela De Santo, Jamie Cavenagh, Michael Dennis, MDMRCP,FRCPath, Ram Malladi, MRCP, FRCPath, PhD, Shamyla Siddique, BSc.(Hons.), MPhil, Yap Christina, MSci, PhD CStat

Blood (2017) 130 (Supplement 1): 276.

https://doi.org/10.1182/blood.V130.Suppl_1.276.276

Published: 2017

Journal Articles

Treatment of Patients with Therapy-Refractory Acute GvHD with the Novel MSC Product "MSC-Ffm" Resulted in Excellent Response and Low Mortality: Post-Approval Observational Data from 69 Consecutive Patients

Blood (2017) 130 (Supplement 1): 514.

https://doi.org/10.1182/blood.V130.Suppl_1.514.514

Published: 2017

Journal Articles

A Randomised Assessment of Ganetespib Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia: Results of the LI-1 Trial

Michael Dennis, FRCPath, Robert K Hills, DPhil, Ian Thomas, Sunil Gupta, MBBS, MRCP, FRCPath, Nicki Panoskaltsis, MD, Mhairi Copland, PhD BSc, MB, ChB, MRCP, FRCPath, Alan K. Burnett, MD FRCP, Nigel H Russell, MD

Blood (2016) 128 (22): 2827.

https://doi.org/10.1182/blood.V128.22.2827.2827

Published: 2016

Journal Articles

Vorinostat Does Not Improve Outcome in Patients with Acute Myeloid Leukemia and High Risk Myelodysplasia Treated with Azacitidine: Results of the UK Trials Acceleration Programme Ravva Trial

Charles Craddock, MD PhD, Aimee E Houlton, BSc, MSc, Paul Ferguson, MBChB MRCP PhD, Manoj Raghavan, Sonia Fox, Louise Dudley, BSc, MRes, Lynn Swun Quek, FRCPath, DPhil, MBBS, Jamie D. Cavenagh, Michael Dennis, FRCPath, Mary Frances McMullin, MD, Srinivas P Pillai, Richard Kelly, BSc, MD, Shamyla Siddique, Keith Wheatley, DPhil, Paresh Vyas, BM, DPhil, FRCP, FRCPath

Blood (2016) 128 (22): 1065.

https://doi.org/10.1182/blood.V128.22.1065.1065

Published: 2016

Journal Articles

Therapeutic Cyclosporine Exposure Measured As Area Under the Curve (AUC) Significantly Influences the Outcome after Allogeneic Hematopoetic Stem Cell Transplant (alloHSCT)

Samar Kulkarni, MD MRCP, FRCPath, John Murray, BSc (hons), MSc, Michael Dennis, FRCPath, Jim Cavet, FRCPath, Anna Z Castleton, FRCPath, Tim Somervaille, MDPhD, Daniel Wiseman, FRCPath, Joanna Tomlins, MSc, Adrian Bloor

Blood (2016) 128 (22): 2237.

https://doi.org/10.1182/blood.V128.22.2237.2237

Published: 2016

Journal Articles

Outcomes with Extracorporeal Photopheresis in the Management of Chronic Gvhd: A Multi-Centre Experience

David Routledge, MSc, BSc (Hons), FRCPath, MRCP, John Murray, BSc (hons), MSc, Fiona Dignan, MD, Amanda Calderwood, Adrian Bloor, Eleni Tholouli, Therese Callaghan, Muhammad Ameer Saif, MD FRCPath, MBBS, MRCP, Michael Dennis, FRCPath, James Cavet, FRCPath, Samar Kulkarni, MD MRCP, FRCPath

Blood (2016) 128 (22): 4595.

https://doi.org/10.1182/blood.V128.22.4595.4595

Published: 2016

Journal Articles

Retrospective Analysis of Seasonal Respiratory Viral Infections (SRVI) in Hematology, Lymphoma and Oncology Patients

Samar Kulkarni, MD MRCP, FRCPath, Stephanie Michail, MBBS, Charlotte Smith, MSc, Joanna Tomlins, MSc, John Murray, BSc (hons), MSc, Michael Dennis, FRCPath, Jim Cavet, FRCPath, Tim Somervaille, MD PhD, Daniel Wiseman, FRCPath, Anna Z Castleton, FRCPath, Adrian Bloor

Blood (2016) 128 (22): 4608.

https://doi.org/10.1182/blood.V128.22.4608.4608

Published: 2016

Journal Articles

Higher Incidence and Risk of Developing Second Solid Cancers (SSC) after Haematopoetic Stem Cell Transplantation (HSCT) As Compared to General Population

Samar Kulkarni, MD MRCP, FRCPath, John Murray, BSc (hons), MSc, Charlotte Smith, MSc, Stephanie Cleaver, RGN, Michael Dennis, FRCPath, Jim Cavet, FRCPath, Tim Somervaille, MD PhD, Anna Z Castleton, FRCPath, Daniel Wiseman, FRCPath, Joanna Tomlins, MSc, Kaz Mamat, MRCP, Angie Leather, MSc, Rita Angelica, BSc, Adrian Bloor

Blood (2016) 128 (22): 4610.

https://doi.org/10.1182/blood.V128.22.4610.4610

Published: 2016

Journal Articles

Long Term Follow up from the NCRI AML17 Trial of Attenuated Arsenic Trioxide and ATRA Therapy for Newly Diagnosed and Relapsed Acute Promyelocytic Leukaemia

Nigel H Russell, MD, Alan K. Burnett, MD FRCP, Robert K Hills, DPhil, Sophie Betteridge, PhD, Michael Dennis, FRCPath, Richard Dillon, MA, MRCP, FRCPath, David Grimwade, PhD FRCPath

Blood (2016) 128 (22): 897.

https://doi.org/10.1182/blood.V128.22.897.897

Published: 2016

Journal Articles

Use of CMV Unselected Blood Products Does Not Increase the Risk of CMV Reactivation in Patients Undergoing Hematopoetic Stem Cell Transplant (HSCT)

Jayne Peters, MRCP, Jonathon Elliott, MRCP, Adrian Bloor, FRCPath, Michael Dennis, FRCPath, John Murray, MSc, Jim Cavet, FRCPath, Tim Somervaille, Sven Armin Sommerfeld, MRCP, Ken Mutton, FRCPath, Kaz Mamat, MRCP, Malcolm Guiver, PhD, Samar Kulkarni, FRCPath

Blood (2015) 126 (23): 2346.

https://doi.org/10.1182/blood.V126.23.2346.2346

Published: 2015

Journal Articles

Incidence of Thrombotic Complications with Use of Peg-Asparginase in Treatment for Acute Lymphoblastic Leukemia (ALL) in Adults and Young Adolescent Patients

David JM Routledge, MRCP, Joanna Tomlins, MSc, Adrian Bloor, FRCPath, Kaz Mamat, MRCP, Michael Dennis, FRCPath, Jim Cavet, FRCPath, Tim Somervaille, Sven Armin Sommerfeld, MRCP, Samar Kulkarni, FRCPath

Blood (2015) 126 (23): 4864.

https://doi.org/10.1182/blood.V126.23.4864.4864

Published: 2015

Journal Articles

An Operational Definition of Primary Refractory Acute Myeloid Leukaemia Which Allows Early Identification of Patients for Whom Allogeneic Stem Cell Transplantation Represents the Only Curative Therapy

Paul Ferguson, MBChB MRCP PhD, Robert K Hills, DPhil, Angela Grech, Sophie Betteridge, Lars Kjeldsen, MD PhD, Michael Dennis, FRCPath, Paresh Vyas, MD PhD, Alan K. Burnett, MD FRCP, Anthony H. Goldstone, FRCP, FRCPath, Donald Milligan, MD, Richard E. Clark, MD, Nigel H. Russell, MD, Charles Craddock, MDPhD

Blood (2015) 126 (23): 559.

https://doi.org/10.1182/blood.V126.23.559.559

Published: 2015

NARROW

Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML: Results from Matched Comparisons to Historical Controls

Post Allograft Rituximab Responsive Cytopenia (RRC)

Results of a Phase 2 Trial of the Monocyte-Targeted Histone Deacetylase Inhibitor Tefinostat (CHR-2845) in Chronic Myelomonocytic Leukemia (CMML) — the UK Monocle Study

Children and Adults with Steroid-Refractory Acute Graft-Versus-Host Disease Respond to Treatment with the Mesenchymal Stroma Cell Preparation "MSC-FFM": Treatment Results for 92 Consecutive Patients

The Achievement of Complete Remission Is Associated with Improved Quality of Life in Non-Intensively Treated Patients with Acute Myeloid Leukemia: Results of the UK NCRI LI-1 Tria

Therapy-Related Myeloid Neoplasms with Balanced Chromosome Rearrangements Frequently Arise from Pre-Existing Clonal Haematopoiesis

Treatment Disparities in Minority Groups with Multiple Myeloma at a Large Safety-Net Hospital

An Evaluation of 17 Years of Low Dose Cytarabine As Therapy for AML Patients Not Fit for Intensive Treatment, Including Patients with Adverse Cytogenetics, Shows Improving Survival, Potential Underutilisation and Highlights the Need for New Therapy

Combined Azacitidine and High Dose Lenalidomide Therapy Is Well Tolerated and Clinically Active in Patients Who Relapse after Allogeneic Stem Cell Transplantation for Actue Myeloid Leukemia: Results of the Uk Trials Acceleration Programme Viola Trial

Treatment of Patients with Therapy-Refractory Acute GvHD with the Novel MSC Product "MSC-Ffm" Resulted in Excellent Response and Low Mortality: Post-Approval Observational Data from 69 Consecutive Patients

A Randomised Assessment of Ganetespib Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia: Results of the LI-1 Trial

Vorinostat Does Not Improve Outcome in Patients with Acute Myeloid Leukemia and High Risk Myelodysplasia Treated with Azacitidine: Results of the UK Trials Acceleration Programme Ravva Trial

Therapeutic Cyclosporine Exposure Measured As Area Under the Curve (AUC) Significantly Influences the Outcome after Allogeneic Hematopoetic Stem Cell Transplant (alloHSCT)

Outcomes with Extracorporeal Photopheresis in the Management of Chronic Gvhd: A Multi-Centre Experience

Retrospective Analysis of Seasonal Respiratory Viral Infections (SRVI) in Hematology, Lymphoma and Oncology Patients

Higher Incidence and Risk of Developing Second Solid Cancers (SSC) after Haematopoetic Stem Cell Transplantation (HSCT) As Compared to General Population

Long Term Follow up from the NCRI AML17 Trial of Attenuated Arsenic Trioxide and ATRA Therapy for Newly Diagnosed and Relapsed Acute Promyelocytic Leukaemia

Use of CMV Unselected Blood Products Does Not Increase the Risk of CMV Reactivation in Patients Undergoing Hematopoetic Stem Cell Transplant (HSCT)

Incidence of Thrombotic Complications with Use of Peg-Asparginase in Treatment for Acute Lymphoblastic Leukemia (ALL) in Adults and Young Adolescent Patients

An Operational Definition of Primary Refractory Acute Myeloid Leukaemia Which Allows Early Identification of Patients for Whom Allogeneic Stem Cell Transplantation Represents the Only Curative Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only